Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Predictive Role of Computer Simulation in Assessing Signaling Pathways of Crizotinib-treated A549 Lung Cancer Cells

  • Xia, Pu (Department of Biochemistry and Molecular Biology, Basic Medical College, China Medical University) ;
  • Mou, Fei-Fei (Shijiazhuang Medical College) ;
  • Wang, Li-Wei (Institute of Biomedical Engineering, Chinese Academy of Medical Science)
  • Published : 2012.07.31
Download PDF
⟨ Previous Next ⟩

Abstract

Non-small-cell lung cancer (NSCLC) is a leading cause of cancer deaths worldwide. Crizotinib has been approved by the U.S. Food and Drug Administration for the treatment of patients with advanced NSCLC. However, understanding of mechanisms of action is still limited. In our studies, we confirmed crizotinib-induced apoptosis in A549 lung cancer cells. In order to assess mechanisms, small molecular docking technology was used as a preliminary simulation of signaling pathways. Interesting, our results of experiments were consistent with the results of computer simulation. This indicates that small molecular docking technology should find wide use for its reliability and convenience.

Keywords

References

  1. Daopin S, Piez KA, Ogawa Y, et al (1992). Crystal structure of transforming growth factor-beta 2: an unusual fold for the superfamily. Science, 257, 369-73. https://doi.org/10.1126/science.1631557
  2. Greenlee RT, Murray T, Bolden S, et al (2000). Cancer statistics, 2000. CA Cancer J Clin, 50, 7-33. https://doi.org/10.3322/canjclin.50.1.7
  3. Hallberg B, Palmer RH (2010). Crizotinib--latest champion in the cancer wars? N Engl J Med, 363, 1760-2. https://doi.org/10.1056/NEJMe1010404
  4. Janku F, Stewart DJ, Kurzrock R (2010). Targeted therapy in non-small-cell lung cancer -- is it becoming a reality? Nat Rev Clin Oncol, 7, 401-14. https://doi.org/10.1038/nrclinonc.2010.64
  5. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
  6. Kwak EL, Bang YJ, Camidge DR, et al (2010). Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med, 363, 1693-703. https://doi.org/10.1056/NEJMoa1006448
  7. Lam WK, White NW, Chan-Yeung MM (2004). Lung cancer epidemiology and risk factors in Asia and Africa. Int J Tuberc Lung Dis, 8, 1045-57.
  8. Lengauer T, Rarey M (1996). Computational methods for biomolecular docking. Curr Opin Struct Biol, 6, 402-6. https://doi.org/10.1016/S0959-440X(96)80061-3
  9. Lynch TJ, Bell DW, Sordella R, et al (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med, 350, 2129-39. https://doi.org/10.1056/NEJMoa040938
  10. McDermott U, Iafrate AJ, Gray NS, et al (2008). Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res, 68, 3389-95. https://doi.org/10.1158/0008-5472.CAN-07-6186
  11. Paez JG, Janne PA, Lee JC, et al (2004). EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science, 304, 1497-500. https://doi.org/10.1126/science.1099314
  12. Pao W, Miller V, Zakowski M, et al (2004). EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA, 101, 13306-11. https://doi.org/10.1073/pnas.0405220101
  13. Qin BY, Lam SS, Correia JJ, et al (2002). Smad3 allostery links TGF-beta receptor kinase activation to transcriptional control. Genes Dev, 16, 1950-63. https://doi.org/10.1101/gad.1002002
  14. Schmierer B, Hill CS (2007). TGFbeta-SMAD signal transduction: molecular specificity and functional flexibility. Nat Rev Mol Cell Biol, 8, 970-82. https://doi.org/10.1038/nrm2297
  15. Subramanian J, Govindan R (2008). Molecular genetics of lung cancer in people who have never smoked. Lancet Oncol, 9, 676-82. https://doi.org/10.1016/S1470-2045(08)70174-8
  16. Sukits SF, Lin LL, Hsu S, et al (2001). Solution structure of the tumor necrosis factor receptor-1 death domain. J Mol Biol, 310, 895-906. https://doi.org/10.1006/jmbi.2001.4790
  17. Taylor RD, Jewsbury PJ, Essex JW (2002). A review of protein-small molecule docking methods. J Comput Aided Mol Des, 16, 151-66. https://doi.org/10.1023/A:1020155510718
  18. Wang Z, Canagarajah BJ, Boehm JC, et al (1998). Structural basis of inhibitor selectivity in MAP kinases. Structure, 6, 1117-28. https://doi.org/10.1016/S0969-2126(98)00113-0
  19. Xu ZY, Blot WJ, Xiao HP, et al (1989). Smoking, air pollution and the high rates of lung cancer in Shenyang, China. J Natl Cancer Inst, 81, 1800-6. https://doi.org/10.1093/jnci/81.23.1800
  20. Yang JM (2004). Development and evaluation of a generic evolutionary method for protein-ligand docking. J Comput Chem, 25, 843-57. https://doi.org/10.1002/jcc.20013
  21. Yang JM, Chen CC (2004). GEMDOCK: a generic evolutionary method for molecular docking. Proteins, 55, 288-304. https://doi.org/10.1002/prot.20035
  22. Zhou S, Buckhaults P, Zawel L, et al (1998). Targeted deletion of Smad4 shows it is required for transforming growth factor beta and activin signaling in colorectal cancer cells. Proc Natl Acad Sci USA, 95, 2412-6. https://doi.org/10.1073/pnas.95.5.2412

Cited by

  1. Crizotinib may be used in Lewis lung carcinoma: A novel use for crizotinib vol.30, pp.1, 2013, https://doi.org/10.3892/or.2013.2424